Skip to main content
Figure 1 | Cardiovascular Diabetology

Figure 1

From: Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes

Figure 1

Eplerenone improved hyperlipidemia and cardiac hypertrophy in ZDF rats. After sixteen weeks of treatment, (A) physical and plasmatic parameters, and (B) cardiac structure and function in ZL, ZDF and ZDF-treated rats (n = 10, each group). Representative photographs of rats and Echo-Doppler images for each group are also shown. (C) Pro-hypertrophic ANP expression in the hearts. Ch, cholesterol; TAG, triglycerides; FFA, free fatty-acid; HDL, high-density lipoproteins; HW, heart weight; FL, femur length. LVPW, left-ventricular posterior wall and IVS, inter-ventricular septum (IVS) thicknesses; LVDD, left ventricular diastolic and LVSD, left ventricular systolic diameters; EF, ejection fraction and Dec. T, deceleration time. *p < 0.05 and **p < 0.01 vs. ZL. †p < 0.05 and ††p < 0.01 vs. ZDF rats.

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840